Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Engrail Therapeutics
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- NeuroCycle Therapeutics, Inc.